Roche, Genentech report study failure for Avastin combination aimed at stomach cancer
NEW YORK – Genentech said Tuesday the combination of its blockbuster cancer drug Avastin and Xeloda did not meet a late-stage study goal of extending the lives of advanced stomach cancer patients.
Read more on Minneapolis-St. Paul Star Tribune
Roche’s Avastin fails in stomach cancer trial
ZURICH (Reuters) – Roche Holding’s cancer drug Avastin missed its main target in a late-stage trial when used with chemotherapy to treat patients with advanced stomach cancer, the Swiss drugmaker said on Tuesday.
Read more on Reuters